MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Purchases $46,750.00 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith acquired 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was acquired at an average cost of $1.87 per share, for a total transaction of $46,750.00. Following the completion of the purchase, the director now directly owns 1,130,060 shares of the company’s stock, valued at approximately $2,113,212.20. This represents a 2.26 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

MAIA Biotechnology Trading Down 0.5 %

MAIA opened at $2.00 on Friday. MAIA Biotechnology, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $5.99. The stock has a market capitalization of $50.66 million, a P/E ratio of -1.45 and a beta of 0.14.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.21. Equities analysts forecast that MAIA Biotechnology, Inc. will post -1.3 EPS for the current fiscal year.

Institutional Investors Weigh In On MAIA Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ground Swell Capital LLC purchased a new stake in MAIA Biotechnology in the 2nd quarter valued at about $56,000. Geode Capital Management LLC boosted its stake in shares of MAIA Biotechnology by 22.9% in the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after buying an additional 35,821 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of MAIA Biotechnology in the third quarter valued at approximately $31,000. 5.65% of the stock is owned by hedge funds and other institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.